At a glance
Small experimental human studies show biological activity; a separate case report illustrates a serious harm signal after reported exposure. These evidence types inform different questions and cannot provide a reliable population risk estimate.
Identity & scope
Melanotan II is a cyclic melanocortin analogue, distinct from Melanotan I and bremelanotide/PT-141. Evidence for these molecules is not interchangeable.
What the research shows
- The pilot observed pigmentation in two participants and nausea, fatigue/somnolence and erection-related effects.
- A small crossover study found measurable erection responses in some men with psychogenic erectile dysfunction.
Critical interpretation
An acute response is not a treatment outcome
The early studies measured pigmentation or erections under experimental monitoring. Those observations show a pharmacological signal, but not durable improvement in health, sexual wellbeing or cosmetic safety. The selected participants and brief observation also limit generalisability. Small experiments are particularly poor at identifying uncommon outcomes, so a response in most participants should not be presented as a dependable benefit-to-risk estimate. [1] [2]
Case reports identify possibilities, not probabilities
The priapism report matters because the outcome was serious, not because it establishes how frequently it occurs. Temporal association and a plausible exposure history warrant attention, while the absence of chemical verification and an unexposed comparison limit causal inference. It would be equally misleading to dismiss it because it is one case or to assign its event rate to all products. The evidence gap is a need for reliable exposure, formulation and safety data, not an invitation to infer safety from the small favourable experiments. [3]
Do not substitute a related melanocortin
A response to Melanotan II is evidence about the molecule and preparation actually tested. It cannot establish an equivalent response to Melanotan I, PT-141 or another receptor agonist. Likewise, a study of a related clinical drug cannot settle the identity, benefit or safety of this catalogue material. [1] [2]
Limitations & uncertainties
- Short experiments cannot resolve uncommon or long-term adverse outcomes.
- A monitored experimental preparation and route do not establish equivalence to a commercial vial or nasal spray.
Open research questions
- What would adequately powered, longer-term research show about benefit, harms and the exact formulation?
Selected papers & source records
Download bibliography1. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (opens in a new tab)
Dorr RT, Lines R, Levine N, et al. (1996). Life Sciences. DOI: 10.1016/0024-3205(96)00160-9 (opens in a new tab) · PMID 8637402
- Design & population
- Single-blind saline-controlled early study in three healthy men.
- What the study found
- Pigmentation increased in two men. Nausea, yawning, erections and fatigue/somnolence were observed.
- Limits on interpretation
- Three participants and brief follow-up cannot establish general safety or a dependable clinical effect.
2. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study (opens in a new tab)
Wessells H, Fuciarelli K, Hansen J, et al. (1998). Journal of Urology. DOI: 10.1016/S0022-5347(01)62903-3 (opens in a new tab) · PMID 9679884
- Design & population
- Double-blind placebo-controlled crossover experiment in ten men, using instrumental erection monitoring.
- What the study found
- Clinically apparent erections developed in eight of ten men after Melanotan II.
- Limits on interpretation
- Small selected population and acute experimental responses, not a long-term safety or treatment trial for supplied formats.
3. Melanotan Tanning Injection: A Rare Cause of Priapism (opens in a new tab)
Mallory CW, Lopategui DM, Cordon BH (2021). Sexual Medicine. DOI: 10.1016/j.esxm.2020.100298 (opens in a new tab) · PMID 33460908
- Design & population
- Clinical case report following self-reported Melanotan-II exposure.
- What the study found
- Prolonged ischaemic priapism required surgery; impaired erectile function was reported during follow-up.
- Limits on interpretation
- One case cannot estimate event frequency or isolate causality, and the reported product was not independently chemically verified.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
Search & review scope
Primary PubMed and journal discovery for early human experiments.. Checked 9 November 2026.
Selected early pigmentation/erection experiments and a full-text serious-adverse-event case report.
Not exhaustive pharmacovigilance. The case report does not establish product composition, causality or event incidence; no current clinical approval claim is made.
Recorded search terms
- site.pubmed.ncbi.nlm.nih.gov melanotan II erections 1998 double blind crossover
- Synthetic melanotropic peptide initiates erections Wessells
- 9679884 doi
- Melanotan II priapism case report PubMed renal infarction
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. Melanotan II: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/melanotan-ii.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.